By Industry News
Edison, N.J. – December 16, 2020, 2020 – MTF Biologics® has received the American Podiatric Medical Association (APMA) Seal of Approval for two MTF Biologics Wound Care tissues, SomaGen® Meshed, Allograft Dermal Matrix and Leneva®, Allograft Adipose Matrix. To receive the seal, both tissues were reviewed by a panel of experienced APMA podiatric physicians.
The APMA Seal of Approval is granted to products that are beneficial to foot health. Companies must provide comprehensive information on each product: objective data from clinical and/or laboratory studies, intended use, patents, composition, and evidence of quality control. A detailed review is conducted by each committee member, and a recommendation is then sent to the APMA Board of Trustees, which may either accept or reject the recommendation.
"Receiving the APMA Seal of Approval will give podiatrists and clinicians continued confidence that SomaGen Meshed and Leneva are revolutionary and life-changing foot health tissues forms,” said Kim Rounds, Vice President and General Manager, MTF Biologics’ Wound Care Franchise. "MTF Biologics is committed to saving and healing lives by providing the highest quality tissue forms. We are proud to have the APMA Seal of Approval awarded to SomaGen Meshed and Leneva.”
“The APMA Seal of Approval is awarded only to the top podiatric products after a rigorous scientific review indicating they meet specific standards,” said APMA Executive Director and CEO James R. Christina, DPM. “MTF Biologics SomaGen Meshed and Leneva have received our coveted Seal of Approval in recognition of their benefits in healing complex and chronic wounds.”
SomaGen Meshed is an acellular human reticular dermal allograft with a unique meshed design that provides a scaffold to support the treatment of a variety of complex wounds. SomaGen Meshed, and its biocompatible design, provides immediate wound coverage without the need for autologous skin grafting, lowering costs and saving time without compromising patient outcomes.
Leneva is a first-of-its-kind human adipose tissue for replacement of damaged or inadequate adipose tissue matrix. As an all-natural extracellular matrix, Leneva may also be used for the reinforcement or supplemental support in underlying adipose tissue matrix as the result of damage or naturally occurring defects.
MTF Biologics is committed to offering advanced, safe, clinically proven, and cost-effective allograft solutions for chronic and complex wounds.
About MTF Biologics Wound Care
MTF Biologics Wound Care is a division of MTF Biologics, a leading non-profit tissue bank. The Wound Care division is dedicated to developing highly advanced, safe, clinically-based and cost-effective wound care solutions that work in concert with the body's natural healing process. For more information, visit www.mtfbiologics.org.
About the American Podiatric Medical Association
Founded in 1912, the American Podiatric Medical Association (APMA), headquartered in Bethesda, MD, is the leading resource for foot and ankle health information. Currently, the organization represents a vast majority of the estimated 15,000 podiatrists in the country. In addition to the national headquarters, APMA boasts 53 state component locations throughout the United States and its territories, as well as affiliated societies. For more, visit www.apma.org.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.